DOI: 10.11648/j.js.20261403.13 ISSN: 2330-0930

Safety of Safil® Polyglactin Mesh in Implant-based Breast Reconstruction: A Single-center Retrospective Analysis

Pedro Montalban-Valverde, Monica Pujol-Canadell, Marta Valor-Soteras, Irene Fita-Esteban, Marta Eguia-Larrea, Luis Munoz-Bellvis
Show PDF Cite
Synthetic absorbable meshes have emerged as a viable alternative to acellular dermal matrices (ADMs) in prosthetic breast reconstruction, offering potential advantages in safety, cost, and handling. Safil® Mesh, a synthetic absorbable polyglactin mesh, has been increasingly adopted in clinical practice; however, real-world data on its performance remain limited. This study aimed to evaluate the safety and clinical performance of Safil® Mesh in breast reconstruction procedures performed at Hospital Universitario de Salamanca. Most patients were classified as ASA II. Safil® Mesh was predominantly used for post-mastectomy breast reconstruction, accounting for 92.2% of cases, with breast cancer as the primary indication in 89%. The mean operative time was approximately 200 minutes, and no intraoperative complications were reported. During follow-up, postoperative complications occurred in 13.6% of surgeries, most commonly prosthesis extrusion (3%), infection (2%), and hematoma (2%), with no complications directly attributed to the mesh. Surgical reintervention was required in 8% of patients, mainly due to implant-related issues. These findings are consistent with previously published long-term observational data on synthetic absorbable meshes, which demonstrate comparable or lower complication rates relative to ADM-based reconstructions. Overall, Safil® Mesh demonstrated a favorable safety profile, with no intraoperative complications and a low incidence of postoperative adverse events. The absence of mesh-related complications and outcomes comparable to those reported in the literature support Safil® Mesh as a reliable alternative to ADMs. Further prospective, multicenter studies are warranted to confirm these findings and assess long-term outcomes.

More from our Archive